key: cord-1025956-n288cnap authors: Amani, B.; Khanijahani, A. title: Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials date: 2020-06-12 journal: nan DOI: 10.1101/2020.06.05.20122705 sha: c014305a88e939a813b0664319a4f67190d96c52 doc_id: 1025956 cord_uid: n288cnap Background & Objective: The efficacy and safety of Hydroxychloroquine (HCQ) in treating coronavirus disease COVID-19 pandemic is disputed. This study aimed to examine the efficacy and safety of HCQ plus standard of care in COVID-19 patients. Methods: PubMed, The Cochrane Library, Embase, and web of sciences were searched up to June 1, 2020. The references list of the key studies was reviewed for additional relevant resources. Clinical studies registry databases were searched for identifying potential clinical trials. The quality of the included studies was evaluated using the Cochrane Collaborations tool. Meta-analysis was performed using RevMan software (version 5.3). Results: Three randomized controlled trials with total number of 242 patients were identified eligible for meta-analysis. No significant differences were observed between HCQ and standard care in terms of viral clearance (Risk ratio [RR] = 1.03; 95% confidence interval [CI] = 0.91, 1.16; P= 0.68), disease progression (RR=0.92; 95% CI= 0.10, 0.81; P=0.94), Chest CT (RR=1.40; 95% CI= 1.03, 1.91; P=0.03). There is a significant difference between HCQ and standard care for adverse events (RR=2.88; 95% CI= 1.50, 5.54; P=0.002). Conclusion: Although the current meta-analysis failed to confirm the efficacy and safety of HCQ in the treatment of COVID-19 patients, further rigorous randomized clinical trials are necessary to evaluate conclusively the efficacy and safety of HCQ against COVID-19. Keyword: Coronavirus Disease; COVID-19; SARS-CoV-2; Hydroxychloroquine; Efficacy; Safety Therefore, there is an urgent need to examine and conclude on this issue based on available evidence. The purpose of this study was to examine the efficacy and safety of HCQ in COVID-19 patients. The study protocol was registered in the international prospective reregister of systematic review (PROSPERO) with the registration number of CRD42020179425 . We used the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist when writing this report [24] . A systematic review of the relevant literature was conducted in PubMed, Cochrane Library, Embase and Google scholar up to June 1, 2020. The references list of the final studies and review articles were reviewed for more citations. The European Union Clinical Trials Register, Clinical trial Gov. and Chinese Clinical Trial Registry (ChiCTR) were also searched. Search terms included 2019-nCoV, SARS-CoV-2, COVID-19, and Hydroxychloroquine which were usually limited to title and abstract of the articles in our search strategy. There was no restriction on the language. Two researchers were independently screened the identified studies based on the inclusion criteria. Disagreements were resolved by discussion among the authors. The following inclusion criteria were used for selecting the articles: (1) Patients with confirmed COVID-19; (2) HCQ as intervention; (3) Standard treatment as control; (4) Randomized controlled trial as study design; (5) and clinical recovery, mortality rate or any adverse events as an outcome. Other studies and reports such as letter to the editor, case reports, editorial comments, observational studies and animal models were excluded Cochrane Collaboration's tool was used to assess the risk of bias in the selected studies. Information on the study characteristics (place, design, and duration), patient's characteristics (age, sex, and number of patients), intervention and control (treatment protocol), efficacy outcomes (clinical improvement and mortality rate), and adverse events were extracted. Both processes were independently performed by two authors, and disagreements were resolved by discussion among the authors . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.05.20122705 doi: medRxiv preprint A meta-analysis was conducted to compare the efficacy and safety of HCQ versus standard treatment using RevMan (version 5.3) software. For dichotomous variables, risk ratio (RR) and a 95% confidence interval (CI) were used. Statistical heterogeneity was evaluated using the I2 and Chi-square tests with a significance level p < 0.05. The random-effects and fixed-effect methods were used for studies with heterogeneity high and low to moderate and, respectively. The process of selecting studies 23, 25] were included in the meta-analysis. [ Figure 1 . goes here] The main characteristics of selected are presented in Table. 1. Chen and et al [22] conducted a randomized clinical trial to examine the efficacy of HCQ in patients with confirmed COVID-19 in China. 62 patients were randomly assigned into two groups. According to the findings, HCQ resulted in significant improvement in the HCQ treatment group versus the control group (80.6% vs. 54.8%, P < 0.05). There was a significant difference in fever and cough between two groups (P < 0.05). Tang et al [23] examined the efficacy and safety of HCQ patients with confirmed COVID-19. They found that HCQ did not result in clinical improvement of COVID-19 patients. At the endpoint, 85.4% of HCQ -treated patients were cured compared to 81.3% in the control group. Chen J et al [25] evaluated the efficacy and safety of HCQ patients with COVID-19 in China. Thirty patients were randomly assigned to HCQ and control groups. At the end of the study, 86.7% of patients in the HCQ group and 93.3% of patients in the control group were cured (P ＞ 0.05). Quality assessment of the studies and risk of bias, using the Cochrane Collaboration's tool, is presented in Figure. 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2020. The purpose of this study was to examine the efficacy and safety of HCQ compared to standard intervention for COVID-19. Although there is no currently proven treatment for COVID-19, several treatment strategies have been suggested for this condition. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.05.20122705 doi: medRxiv preprint A few RCTs examined the efficacy and safety of HCQ in treating COVID-19. The findings of our meta-analysis showed that there is no significant difference between HCQ and standard care in patients with confirmed COVID-19 (P>0.05). Previously published meta-analyses [26] [27] [28] on observational studies and randomized controlled trials found no clinical benefits for HCQ in comparison with standard care for COVID-19 patients. These studies confirm our findings. It should be noted that the most of included studies in these meta-analyses were observational. There are some concerns regarding the limitations of these studies which should be considered. All kinds of biases such as confounding, reverse causation, statistical considerations and other issues are the limitations of these studies in the estimation of drug efficacy and safety [29] . The Agency for Healthcare Research and Quality (AHRQ) has provided recommendations on including observational studies into the comparative effectiveness review process for comparing medical interventions [30] . Gautret et al [31] suggested that the causes of insufficient response to treatment with HCQ in the non-respondents with COVID-19 should be examined by factors such as SARS-CoV-2 strains, genome, and other factors associated with the metabolism of HCQ in patients. A possible mechanism for HCQ inefficiency was explained by Sandeep and McGregor [32] using virtualized quantum mechanical modeling. However, Yao et al [33] found that HCQ was more potent than Chloroquine inhabiting SARS-CoV-2 in vitro. Generally, the evidence for the efficacy and safety of HCQ is controversial. A meta-analysis by Shamshirian et al [28] confirms these findings and showed that HCQ treatment is associated with higher mortality (1.5 times). However, another Meta-analysis study showed that there was no significant difference between HCQ and control treatment for mortality [26] . Some studies supported the synergistic effect of HCQ with Azithromycin on COVID-19. A study [34] demonstrated the moderate in vitro effect of HCQ alone and its synergistic effect as combination therapy with Azithromycin on COVID-19. In an open-label non-randomized clinical trial, Gautret et al [31] found that 100% of patients received HCQ and Azithromycin as combination therapy were cured. These authors found similar results in another study. A metaanalysis showed that HCQ alone or as the combination with AZM in comparison with the control group was not effective in COVID-19 and was associated with higher mortality rates [35] . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.05.20122705 doi: medRxiv preprint A newly published meta-analysis showed that not only the combination of HCQ and azithromycin did not result in any significant clinical improvement in COVID-19 patients, but also it was associated with 2.5 times higher mortality in comparison to the control group. A meta-analysis of the adverse effects of long-term Azithromycin use in patients with chronic lung diseases showed that Azithromycin is associated with increasing the risk of bacterial resistance (2.7-fold) [36] . Our meta-analysis showed that there is a significant difference between HCQ and the control group for adverse events. Reported adverse events in RCTs were mild. Adverse effects of antimalarial are usually rare and mild [37] . Gastric symptoms are a prevalent adverse effect of HCQ [38, 39] , Other adverse events are including Cutaneous [40] , headache [41] [42] [43] , Cardiomyopathy [44] [45] [46] and Retinopathy [47] [48] [49] [50] [51] . Regarding the short-term follow-up of the studies, it is recommended that patients received HCQ should be monitored for possible adverse events for a longer period. The existence of a limited number of studies, high heterogeneity between studies, small sample size, short follow-up period, and lack of rigor methodology of the studies were among the limitations of our study. Nevertheless, the findings of this study can be beneficial for guiding clinicians in decisions regarding COVID-19 treatment. According to the findings of this study, HCQ appears to be not effective and safe in the treatment of patients with COVID-19. Given that there are limited RCTs on the efficacy and safety of HCQ in COVID-19, there are needed more evidence. Further well-designed and high quality randomized controlled trials with large sample size are necessary to establish the efficacy and safety of HCQ for this disease. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.05.20122705 doi: medRxiv preprint No potential Competing interests relevant to this article was reported No funding was obtained for this study. We are thankful to the authors of the studies included in this systematic review and metaanalysis. BaA and BeA systematically reviewed the search results and selected the relevant studies. BaA performed the formal analysis. All authors performed the literature search, wrote the manuscript, and reviewed the manuscript. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.05.20122705 doi: medRxiv preprint Figure 1 . Flowchart of study selection process . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.05.20122705 doi: medRxiv preprint Inclusion criteria Outcomes . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.05.20122705 doi: medRxiv preprint Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) Hydroxychloroquine in COVID-19: A systematic review and meta-analysis. medRxiv Virological and clinical cure in COVID 19 patients treated with hydroxychloroquine: a systematic review and meta analysis Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis The limitations of observation studies for decision making regarding drugs efficacy and safety Methods guide for effectiveness and comparative effectiveness reviews [Internet] (Agency for Healthcare Research and Quality (US) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Energetics Based Modeling of Hydroxychloroquine and Azithromycin Binding to the SARS-CoV-2 Spike (S) Protein-ACE2 Complex In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) In vitro testing of hydroxychloroquine and azithromycin on SARS-CoV-2 shows 1 synergistic effect 2. lung Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel medicine and infectious disease Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects Hydroxychloroquine-drug characterization and the most frequently observed adverse reactions in the group of patients with diagnosed alopecia cicatricans Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial Treatment of lupus skin involvement with quinacrine and hydroxychloroquine Dose response relationship of hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a randomised control study Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study Hydroxychloroquine retinopathy: a review of imaging Hydroxychloroquine-Induced Retinal Toxicity Recommendations on screening for chloroquine and hydroxychloroquine retinopathy Hydroxychloroquine retinopathy-implications of research advances for rheumatology care